Jotbody

Founded in 2020, Jotbody (HK) Limited is a pioneering biotechnology company specializing in nanobody research and extracellular vesicle (EV) technologies. Backed by a team of experienced scientists and industry experts, Jotbody is dedicated to advancing global research and development through innovative solutions and high-quality scientific services.

Jotbody offers a comprehensive range of nanobody discovery and development services, including antigen design, nanobody humanization, affinity maturation, protein expression, and coupling modification. The company’s expertise extends to customizing camelid VHH and shark vNAR nanobodies, providing tailor-made solutions for biopharmaceutical and life science applications.

Recognized by Forbes Asia among the “100 Companies to Watch in 2023,” Jotbody has also established itself as a leader in extracellular vesicle research. Since 2014, the company has collaborated with renowned academic and industry partners—most notably Dr. Minh Le from the National University of Singapore—to advance therapeutic applications of EVs across cancer, neurodegenerative, cardiovascular, and inflammatory diseases.

Through its advanced EV research platform, Jotbody delivers end-to-end services including isolation, purification, characterization, omics analysis, functionalization, and CDMO solutions.

Driven by a vision to empower life sciences through nanobody precision and EV innovation, Jotbody is committed to scientific excellence, collaboration, and innovation, supporting researchers in over 20 countries with cutting-edge tools and technologies.